News | Focused Ultrasound Therapy | August 22, 2017

Insightec Announces Expanded Reach of MR-Guided Focused Ultrasound

More than 1,000 patients treated with Exablate Neuro system

Insightec Announces Expanded Reach of MR-Guided Focused Ultrasound

August 22, 2017 — Insightec announced recently that worldwide adoption of magnetic resonance (MR)-guided focused ultrasound continues to gain momentum as Exablate Neuro patient treatment numbers surpass the 1,000 mark. Medical facilities are ramping up their MR-guided focused ultrasound service and essential tremor patients are now being treated on a weekly basis at many sites, according to the company.

Exablate Neuro delivers focused ultrasound beams without any surgical incision to ablate the Vim of the thalamus, the tiny area of the brain thought to be responsible for causing tremors.

Regulatory approvals in the United States, Canada, Japan, Europe, Israel and Korea contributed to the accelerated adoption of focused ultrasound treatments worldwide. One year ago, on July 11, 2016, the U.S. Food and Drug Administration (FDA) approved Exablate Neuro as the first focused ultrasound device to treat essential tremor in patients who have not responded to medication.

“Having this newly established treatment at Weill Cornell Medical Center allows us to offer a safe and effective, incisionless treatment for patients with disabling tremor,” said M. Kaplitt, M.D., Ph.D., neurosurgeon at Weill Cornell Medical Center.

Essential tremor is a very common neurological condition that causes shaking of the hands, as well as other parts of the body. For most people, the severity of the tremor increases over time to the point where performing everyday tasks is impossible. This can have a significant impact on a person’s quality of life. If medications fail to control symptoms, it may also be treated with radiation or invasive surgical procedures, including traditional thalamotomy or deep brain stimulation.

Focused ultrasound is an incision-less treatment option that minimizes risk of complications such as infection and bleeding, reduces time spent recovering and rapidly returns patients to their lives.

“This past year, since having the focused ultrasound treatment, has simply been life-changing for me and my entire family”, commented Gregg Ley. Ley was treated one year ago at Swedish Medical Center in Seattle, Washington during the FDA pivotal study designed to evaluate the safety and efficacy of Exablate Neuro for the treatment of essential tremor in subjects for whom medications were not effective.

Over 30 Exablate Neuro systems are now actively treating patients for essential tremor as well as various research protocols for additional indications in 10 countries.

For more information: www.insightec.com

Related Content

IBA Gathers Experts on Flash Irradiation During ASTRO
News | Proton Therapy | September 17, 2019
IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019...
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Sun Nuclear Presents Portfolio of Independent Radiotherapy QA Solutions at ASTRO 2019

The PlanCheck module now part of SunCheck, automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent.

News | Quality Assurance (QA) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, running Sept. 15-18 in Chicago, Sun Nuclear...
Varian Unveils Ethos Solution for Adaptive Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian...
Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning

The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning. Image courtesy of Siemens Healthineers.

News | Computed Tomography (CT) | September 15, 2019
Siemens Healthineers debuted two computed tomography (CT) systems dedicated to radiation therapy (RT) planning at the...
Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting
News | Brachytherapy Systems | September 13, 2019
Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the...
Akesis Galaxy SRS System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | September 13, 2019
The Akesis Galaxy, a gamma stereotactic radiosurgery system (SRS) with continuous 360-degree rotational technology, has...
Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019
News | Radiation Oncology | September 13, 2019
Philips will showcase its integrated radiation oncology portfolio at the American Society of Radiation Oncology (ASTRO...
RefleXion Highlights Novel Approach to Radiotherapy at ASTRO 2019

The RefleXion X1 Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. Image courtesy of Reflexion Medical.

News | Radiation Therapy | September 12, 2019
Therapeutic oncology company RefleXion Medical announced it will showcase the RefleXion X1 Machine at the American...